Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Guideline
. 2016 Oct;14(10):1213-1224.
doi: 10.6004/jnccn.2016.0131.

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016

Peter E Clark  1 , Philippe E Spiess  1 , Neeraj Agarwal  1 , Rick Bangs  1 , Stephen A Boorjian  1 , Mark K Buyyounouski  1 , Jason A Efstathiou  1 , Thomas W Flaig  1 , Terence Friedlander  1 , Richard E Greenberg  1 , Khurshid A Guru  1 , Noah Hahn  1 , Harry W Herr  1 , Christopher Hoimes  1 , Brant A Inman  1 , A Karim Kader  1 , Adam S Kibel  1 , Timothy M Kuzel  1 , Subodh M Lele  1 , Joshua J Meeks  1 , Jeff Michalski  1 , Jeffrey S Montgomery  1 , Lance C Pagliaro  1 , Sumanta K Pal  1 , Anthony Patterson  1 , Daniel Petrylak  1 , Elizabeth R Plimack  1 , Kamal S Pohar  1 , Michael P Porter  1 , Wade J Sexton  1 , Arlene O Siefker-Radtke  1 , Guru Sonpavde  1 , Jonathan Tward  1 , Geoffrey Wile  1 , Mary A Dwyer  1 , Courtney Smith  1
Affiliations
Guideline

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016

Peter E Clark et al. J Natl Compr Canc Netw. 2016 Oct.

Abstract

These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
    1. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169:90–95. - PubMed
    1. Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67:1216–1223. - PubMed
    1. Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88:209–216. - PubMed
    1. Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93:485–490. - PubMed

Publication types

MeSH terms

Substances